Preimplantation Genetic Testing (PGT) is a specialized IVF procedure that screens embryos for chromosomal abnormalities or inherited genetic conditions before implantation, helping improve success rates and reduce the risk of genetic disorders.
Market Overview
The preimplantation genetic testing (PGT) market is experiencing substantial growth, driven by the increasing demand for genetic screening during in vitro fertilization (IVF) procedures. PGT involves analyzing embryos for genetic abnormalities before implantation, allowing clinicians to select healthy embryos for transfer, thereby increasing the chances of successful pregnancy and reducing the risk of genetic disorders in offspring.
The global preimplantation genetic testing market is projected to grow from USD 690.2 million in 2025 to USD 1,135.0 million by 2030, at a compound annual growth rate (CAGR) of 10.5% from 2025 to 2030. This growth is attributed to several factors, including:
* Increasing Awareness of Genetic Disorders: Growing awareness among couples about the risk of transmitting genetic disorders to their children is driving the demand for PGT.
* Advancements in Technology: Technological advancements in PGT techniques, such as next-generation sequencing (NGS), have improved the accuracy and efficiency of genetic screening, making it more accessible and reliable.
* Rising Demand for IVF Procedures: The increasing prevalence of infertility and the growing acceptance of IVF procedures are contributing to the growth of the PGT market.
* Growing Disposable Incomes: Rising disposable incomes in developing countries are enabling more couples to afford PGT services.
* Government Support: Supportive government policies and initiatives promoting reproductive health are also contributing to the growth of the PGT market.
Download PDF Brochure
Market Segmentation
The preimplantation genetic testing market can be segmented based on several factors, including:
By Test Type
* Preimplantation Genetic Diagnosis (PGD): PGD is used to detect specific genetic mutations or chromosomal abnormalities in embryos when one or both parents are known carriers of a genetic disorder.
* Preimplantation Genetic Screening (PGS): PGS is used to screen embryos for chromosomal abnormalities, such as aneuploidy (abnormal number of chromosomes), in couples who are not known carriers of a specific genetic disorder but are at risk of having a child with chromosomal abnormalities due to advanced maternal age or recurrent miscarriages.
By Technology
* Next-Generation Sequencing (NGS): NGS is a high-throughput sequencing technology that allows for the simultaneous analysis of multiple genes or entire genomes, providing comprehensive genetic information about embryos.
* Polymerase Chain Reaction (PCR): PCR is a molecular biology technique used to amplify specific DNA sequences, enabling the detection of genetic mutations or chromosomal abnormalities.
* Fluorescence In Situ Hybridization (FISH): FISH is a cytogenetic technique used to detect and localize specific DNA sequences on chromosomes, allowing for the identification of chromosomal abnormalities.
* Comparative Genomic Hybridization (CGH): CGH is a molecular cytogenetic technique used to detect chromosomal copy number variations, such as deletions or duplications.
By End User
* Fertility Clinics: Fertility clinics are the primary end users of PGT services, offering genetic screening to couples undergoing IVF procedures.
* Hospitals and Diagnostic Laboratories: Hospitals and diagnostic laboratories also offer PGT services, either independently or in collaboration with fertility clinics.
* Research Institutes: Research institutes use PGT for research purposes, such as studying the genetic basis of infertility and developing new genetic screening techniques.
By Region
* North America: North America is the largest market for PGT, driven by the high adoption rate of IVF procedures and the presence of advanced healthcare infrastructure.
* Europe: Europe is the second-largest market for PGT, with a growing number of fertility clinics offering genetic screening services.
* Asia Pacific: Asia Pacific is the fastest-growing market for PGT, driven by the increasing prevalence of infertility and the rising disposable incomes in developing countries.
* Latin America: Latin America is an emerging market for PGT, with a growing number of couples seeking genetic screening services.
* Middle East & Africa: The Middle East & Africa region is witnessing increasing adoption of PGT, driven by rising awareness of genetic disorders and government initiatives to improve reproductive health.
Key Market Players
The preimplantation genetic testing market is highly competitive, with several key players offering a range of PGT services and technologies. Some of the leading companies in the market include:
These companies are focused on developing innovative PGT technologies and expanding their service offerings to meet the growing demand for genetic screening during IVF procedures.
Market Trends
Several key trends are shaping the preimplantation genetic testing market:
* Increasing Adoption of NGS Technology: NGS technology is becoming increasingly popular for PGT due to its high accuracy, comprehensive genetic information, and cost-effectiveness.
* Growing Demand for Non-Invasive PGT (niPGT): niPGT involves analyzing cell-free DNA from the spent culture media of embryos, offering a non-invasive alternative to traditional PGT methods that require embryo biopsy.
* Rising Focus on Single-Gene Disorder Testing: PGT is increasingly being used to screen embryos for specific single-gene disorders, such as cystic fibrosis, spinal muscular atrophy, and Huntington’s disease.
* Expanding Applications of PGT: PGT is being explored for new applications, such as selecting embryos for specific traits or characteristics, although ethical considerations surrounding these applications remain a subject of debate.
Request Sample Pages
Challenges and Opportunities
The preimplantation genetic testing market faces several challenges, including:
* High Cost of PGT: The high cost of PGT can be a barrier to access for some couples, particularly in developing countries.
* Ethical Concerns: Ethical concerns surrounding PGT, such as the potential for sex selection or the discarding of embryos with genetic abnormalities, need to be addressed.
* Regulatory Issues: The regulatory landscape for PGT varies across different countries, creating challenges for companies operating in the global market.
Despite these challenges, the PGT market offers significant opportunities for growth:
* Expanding Access to PGT: Efforts to reduce the cost of PGT and increase access to genetic screening services can drive market growth.
* Developing New PGT Technologies: Continued innovation in PGT technologies, such as niPGT and advanced NGS platforms, can improve the accuracy and efficiency of genetic screening.
* Addressing Ethical Concerns: Open and transparent discussions about the ethical implications of PGT can help to build public trust and acceptance of the technology.
Conclusion
The preimplantation genetic testing market is poised for significant growth in the coming years, driven by increasing awareness of genetic disorders, advancements in technology, and rising demand for IVF procedures. While challenges remain, the market offers significant opportunities for companies that can develop innovative PGT technologies and address the ethical concerns surrounding this rapidly evolving field.
The projected CAGR of 10.5% from 2025 to 2030 underscores the strong growth potential of the PGT market, making it an attractive area for investment and innovation.
News From
MarketsandMarkets™
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w …
This email address is being protected from spambots. You need JavaScript enabled to view it.
